266 related articles for article (PubMed ID: 20027102)
1. Private sector contributions to pharmaceutical science: thirty-five summary case histories.
Zycher B; DiMasi JA; Milne CP
Am J Ther; 2010; 17(1):101-20. PubMed ID: 20027102
[TBL] [Abstract][Full Text] [Related]
2. [Does the public sector have an independent research role in the development of drugs?].
Poulsen HE; Grønlykke TB
Ugeskr Laeger; 2003 Apr; 165(16):1674-6. PubMed ID: 12756828
[TBL] [Abstract][Full Text] [Related]
3. The Human Genome Project: a public good.
Hudson K
Health Matrix Clevel; 2002; 12(2):367-75. PubMed ID: 12430360
[No Abstract] [Full Text] [Related]
4. Initial lessons from public-private partnerships in drug and vaccine development.
Wheeler C; Berkley S
Bull World Health Organ; 2001; 79(8):728-34. PubMed ID: 11545329
[TBL] [Abstract][Full Text] [Related]
5. [Mechanism and implication of regulation of the pricing of essential medicines in the private pharmaceutical sector in Mali].
Maïga D; Maïga S; Maïga MD
Med Trop (Mars); 2010 Apr; 70(2):184-8. PubMed ID: 20486360
[TBL] [Abstract][Full Text] [Related]
6. Regulating scientific research: intellectual property rights and the norms of science.
Rai AK
Northwest Univ Law Rev; 1999; 94(1):77-152. PubMed ID: 12784815
[No Abstract] [Full Text] [Related]
7. [An analysis of the pharmaceuticals market in Vietnam].
Simonet D
Sante; 2001; 11(3):155-60. PubMed ID: 11641078
[TBL] [Abstract][Full Text] [Related]
8. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
9. Re-engineering drug discovery and development.
FitzGerald GA
LDI Issue Brief; 2011 Oct; 17(2):1-4. PubMed ID: 22049582
[TBL] [Abstract][Full Text] [Related]
10. The effect of generic competition on the price of brand-name drugs.
Lexchin J
Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
[TBL] [Abstract][Full Text] [Related]
11. The economics of pediatric formulation development for off-patent drugs.
Milne CP; Bruss JB
Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
[TBL] [Abstract][Full Text] [Related]
12. Introducing new contraceptives.
Segal SJ; Coutinho E
Draper Fund Rep; 1986 Dec; (15):27-32. PubMed ID: 12341234
[TBL] [Abstract][Full Text] [Related]
13. A source of innovation.
Gillespie DG
Integration; 1992 Dec; (34):2-7. PubMed ID: 12317827
[TBL] [Abstract][Full Text] [Related]
14. Pathways across the valley of death: novel intellectual property strategies for accelerated drug discovery.
Rai AK; Reichman JH; Uhlir PF; Crossman C
Yale J Health Policy Law Ethics; 2008; 8(1):1-36. PubMed ID: 18564492
[No Abstract] [Full Text] [Related]
15. Balancing health and industrial policy objectives in the pharmaceutical sector: lessons from Australia.
Morgan S; McMahon M; Greyson D
Health Policy; 2008 Aug; 87(2):133-45. PubMed ID: 18295927
[TBL] [Abstract][Full Text] [Related]
16. Public-private partnership: from there to here.
Croft SL
Trans R Soc Trop Med Hyg; 2005 Oct; 99 Suppl 1():S9-14. PubMed ID: 16087204
[TBL] [Abstract][Full Text] [Related]
17. Research, innovation and politics.
Hart DM; Branscomb LM
Nature; 2000 Oct; 407(6804):561-2. PubMed ID: 11034186
[No Abstract] [Full Text] [Related]
18. Industry and academia in transition.
Kennedy D
Science; 2003 Nov; 302(5649):1293. PubMed ID: 14631000
[No Abstract] [Full Text] [Related]
19. Ethics. Private money, public disclosure.
Kaiser J
Science; 2009 Jul; 325(5936):28-30. PubMed ID: 19574366
[No Abstract] [Full Text] [Related]
20. Attrition and translation.
Duyk G
Science; 2003 Oct; 302(5645):603-5. PubMed ID: 14576424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
